July 28th 2025, Bhopal, (M.P.) INDIA: 3B BlackBio Dx Ltd. (3B) along with its subsidiary TRUPCR® Europe Limited (TPE) is pleased to announce that it has entered into a definitive agreement with Avacta Group Plc, London to acquire all the shares of Coris Holding SRL, the parent company of Coris Bioconcept SRL (“Coris”) for an upfront cash consideration of £2.15 Million (including net cash & customary working capital adjustments) with an earnout based on future business performance of up to £0.615 Million payable (the “Acquisition”) totaling to £2.765 Million.
Coris’ product portfolio comprises in vitro diagnostic test kits for AntiMicrobial Resistance (AMR), respiratory, gastroenteric and blood-borne pathogens (bacteria, viruses and parasites), however, it is primarily focused on the antibiotic resistance markers. As part of this portfolio, the company offers a range of rapid lateral flow tests designed to support early and accurate diagnosis at the point of care. Coris also offers a lateral flow test ‘HAT Sero K-SeT’ for detecting antibodies specific to Trypanosoma brucei gambiense in human whole blood, serum or plasma, a product that holds global monopoly. Coris had also developed and launched the First European Lateral Flow Test for detection of COVID.
Since 3B also specializes in IVD products, this acquisition is complementary, as both companies share a focus on in vitro diagnostics, particularly in antimicrobial resistance (AMR) which is a growing global concern. The combined strengths of 3B and Coris create opportunities to expand sales and market reach by leveraging their global distributor networks. The two companies will work collaboratively to promote and distribute each (Formerly – Kilpest India Limited) other’s complementary product lines, enhancing value for partners and customers worldwide.
To know more about this acquisition, please click here
General enquires: info@3bblackbio.com
Corporate Enquiry:
+91 9691680693,+91 9810562700
Orders: info@3bblackbio.com
Tel: 0755 - 4076518, 4077847
